Connect with us

Cannabis News

Will The World Health Organization (W.H.O.) Reclassify Cannabis?

Published

on

Will The World Health Organization (W.H.O.) Reclassify Cannabis?

On February 1, 2019, the World Health Organization announced that cannabis should be reclassified under international drug treaties. The proposed reclassification would remove cannabis and its resin from the definition of a Schedule IV drug under the Single Convention on Narcotic Drugs of 1961.

If accepted, the reclassification would prevent countries relying on international treaties to ban marijuana. Rather, they would just need to ban it under their own laws. The Americans for Safe Access posits that cannabis and the resin were categorized as a Schedule IV substance to motivate western countries to ban the substance.

According to Steph Sherer, the founder and president of Americans for Safe Access,

“We are extremely pleased that the World Health Organization has finally recognized the therapeutic potential of cannabis and its derivatives as a safe and effective medicine. With an international rescheduling or de-scheduling of cannabis, the U.S. government can no longer use the excuse that cannabis has no medical value.”

Further, Dr. Ethan Russo, the director of the International cannabis and Cannabinoids Institute added,

“It is gratifying that the World Health Organization has recognized the scientific fact that cannabis and its derivatives have demonstrable therapeutic properties and can be the base for safe and effective medicines. It is now incumbent upon governments of the USA and other nations to eliminate the barriers to research on cannabis and allow its free commerce across state lines and international frontiers.”

In addition to focusing on cannabis, the WHO also recommended that THC and its isomers be removed from the definition of Schedule II banned substances under the 1971 Convention on Psychotropic Substances and rather, be added as a Schedule I substance under the Single Convention of 1961.

As for cannabidiol, the WHO reported that,

“pure cannabidiol (CBD) should not be scheduled within the International Drug Control Conventions by adding a footnote to the entry for cannabis and cannabis resin in Schedule I of the Single Convention on Narcotic Drugs (1961) to read “Preparations containing predominately cannabidiol and not more than 0.2 percent of delta-9-tetrahydrocannabinol are not under international control.”

The proposal will be brought before the UN commission on Narcotics Drugs in March. The member nations will then vote to either accept or reject the proposal.  There is no telling how the United States will vote. In the United States, cannabis is illegal under federal law and is classified as a Schedule I substance.

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.